A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer
Johanna C. Bendell(Dana-Farber Cancer Institute), Michael Thomas, Celine Pitou(Eli Lilly (United States)), Helge Bischoff(Heidelberg University), Katherine M. Bell‐McGuinn(Memorial Sloan Kettering Cancer Center), Thomas Zander(Integrated Oncology (United States)), Robert M. Campbell(Children's Health Queensland Hospital and Health Service), Daphne L. Farrington(Eli Lilly (United States)), Xuejing Wang(University of Bern), Jimmy J. Hwang(University of California, San Francisco), Scott M. Hynes(Eli Lilly (United States)), Philip W. Iversen(Eli Lilly (United States)), Hans Christian Reinhardt(German Cancer Research Center)
Cited by 30
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Histone Modifications and Cancer
|Cold Spring Harbor Perspectives in Biology|2016|1.1k
High-throughput oncogene mutation profiling in human cancer
|Nature Genetics|2007|996
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
|Journal of Clinical Oncology|2011|684
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
|The Lancet Oncology|2012|541